Wim E. M. Mol
Directeur/Bestuurslid bij Inorbit Therapeutics AB
Profiel
Wim E.
M.
Mol is currently a Director at Inorbit Therapeutics AB.
Previously, he served as the Chief Executive Officer at Pepscan Holding NV, Pepscan Therapeutics BV, Immunovo BV, and Catapult Therapeutics BV.
He also worked as a General Manager at Organon BioSciences NV.
Dr. Mol holds a graduate and doctorate degree from the University of Groningen.
Actieve functies van Wim E. M. Mol
Bedrijven | Functie | Begin |
---|---|---|
Inorbit Therapeutics AB
Inorbit Therapeutics AB Pharmaceuticals: MajorHealth Technology Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Wim E. M. Mol
Bedrijven | Functie | Einde |
---|---|---|
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Algemeen Directeur | 01-01-2021 |
Immunovo BV
Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Algemeen Directeur | - |
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Corporate Officer/Principal | - |
Pepscan Therapeutics BV
Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Algemeen Directeur | - |
Pepscan Holding NV
Pepscan Holding NV Pharmaceuticals: MajorHealth Technology Pepscan Holding NV operates as a holding company with interest in developing immunotherapeutic products in oncology. It offers proprietary technologies for the design, manufacture and use of large combinatorial arrays of peptides, peptide constructs, peptidometics and peptide derivatives. The firm operates through its subsidiaries Pepscan Systems BV and Pepscan Therapeutics BV. The company was founded in 2007 and is headquartered in Lelystad, the Netherlands. | Algemeen Directeur | - |
Opleiding van Wim E. M. Mol
University of Groningen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Pepscan Holding NV
Pepscan Holding NV Pharmaceuticals: MajorHealth Technology Pepscan Holding NV operates as a holding company with interest in developing immunotherapeutic products in oncology. It offers proprietary technologies for the design, manufacture and use of large combinatorial arrays of peptides, peptide constructs, peptidometics and peptide derivatives. The firm operates through its subsidiaries Pepscan Systems BV and Pepscan Therapeutics BV. The company was founded in 2007 and is headquartered in Lelystad, the Netherlands. | Health Technology |
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Health Technology |
Pepscan Therapeutics BV
Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Health Technology |
Immunovo BV
Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Health Technology |
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Commercial Services |
Inorbit Therapeutics AB
Inorbit Therapeutics AB Pharmaceuticals: MajorHealth Technology Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden. | Health Technology |